Cancers | Free Full-Text | Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
Survival analysis in hematologic malignancies: recommendations for clinicians | Haematologica
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Progression-free survival and overall survival. Progression-free... | Download Scientific Diagram
Kaplan-Meier survival curves of progression-free survival and overall... | Download Scientific Diagram
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
Recurrence/progression-free survival and overall survival among... | Download Scientific Diagram
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Comparison of progression-free survival (A) or overall survival (B)... | Download Scientific Diagram
Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials - ScienceDirect
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Estimating progression-free survival in patients with glioblastoma using routinely collected data | Journal of Neuro-Oncology
Progression-free survival and overall survival probabilities. | Download Scientific Diagram
Extrapolation from Progression Free Survival to Overall Survival in Oncology | PPT
Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom?
Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - ScienceDirect
Understanding Overall Survival in Metastatic Breast Cancer
Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
